Head to Head Survey: Biohaven Pharmaceutical (BHVN) vs. Novelion Therapeutics (NVLN)
Biohaven Pharmaceutical (NYSE: BHVN) and Novelion Therapeutics (NASDAQ:NVLN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.
Insider & Institutional Ownership
47.8% of Biohaven Pharmaceutical shares are held by institutional investors. Comparatively, 75.6% of Novelion Therapeutics shares are held by institutional investors. 14.1% of Novelion Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
This table compares Biohaven Pharmaceutical and Novelion Therapeutics’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Biohaven Pharmaceutical||N/A||N/A||-$63.67 million||N/A||N/A|
|Novelion Therapeutics||$13.57 million||5.62||-$52.87 million||($6.99)||-0.59|
Novelion Therapeutics has higher revenue and earnings than Biohaven Pharmaceutical.
This table compares Biohaven Pharmaceutical and Novelion Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current ratings and target prices for Biohaven Pharmaceutical and Novelion Therapeutics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Biohaven Pharmaceutical currently has a consensus target price of $38.00, indicating a potential upside of 21.64%. Novelion Therapeutics has a consensus target price of $8.00, indicating a potential upside of 95.60%. Given Novelion Therapeutics’ higher probable upside, analysts plainly believe Novelion Therapeutics is more favorable than Biohaven Pharmaceutical.
Biohaven Pharmaceutical Company Profile
Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates. Its pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity (NCE) that modulates glutamate, and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate (NMDA) receptor antagonism. Its clinical compound, trigriluzole, is indicated for neurodegenerative diseases and cancer indications, among others. Its pipeline also includes BHV-3000 and BHV-3500, which are in-licensed by the Company for a neurologic indication. It focuses on advancing other mechanistic approaches in orphan and neuroscience indications, and is exploring licenses for additional compounds.
Novelion Therapeutics Company Profile
Novelion Therapeutics Inc, formerly QLT Inc., is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development. The Company holds a portfolio of products through its subsidiary, Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. The Company’s portfolio of products include MYALEPT and JUXTAPID. The Company is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes.
Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.